Falsification and Pharmacovigilance: What Do Patients Get to See and What Should They Do with It?
The ‘Falsified medicines directive’ (2011/62/EU) and the ‘Pharmacovigilance regulation’ (No 1235/2010) will influence some of the information that patients receive about medicines. In both the directive and the regulation, several forms of visual communication are mentioned.
In this discussion piece Dr Karel van der Waarde explores the impact of the latest falsification and pharmacovigilance regulation on pharmaceutical packaging.
Please note: That all fields marked with an asterisk (*) are required.